Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 108

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 108
---
 financial measure defined as net income, plus 
 interest and taxes.                                              |

Risk-Adjusted FYARRO Projections Set forth below is a summary of the risk-adjusted FYARRO projections, which were calculated based on the non risk-adjusted FYARRO projections and probability adjusted to reflect Aadi’s assessment of a 75% probability of success (PoS) to European Union net sales. The risk-adjusted FYARRO projections, as well as the estimated, probability-adjusted unlevered free cash flow, which was calculated based on the risk-adjusted FYARRO projections for the applicable periods are summarized below (in millions):

| Revenue:                     |     |      |    |     | 2025 |    |   |     | 2026 |    |     | 2027 |    |     | 2028 |    |     | 2029 |    |     | 2030 |    |     | 2031 |    |
|:-----------------------------|:----|-----:|---:|:----|-----:|---:|:--|:----|-----:|---:|:----|-----:|---:|:----|-----:|---:|:----|-----:|---:|:----|-----:|---:|:----|-----:|---:|
| FYARRO (PEComa—US)           |     |      |    |     |    $ | 28 |   |     |    $ | 31 |     |    $ | 32 |     |    $ | 33 |     |    $ | 34 |     |    $ | 35 |     |    $ | 36 |
| FYARRO (PEComa—EU royalty)   |     |      |    |     |      |  — |   |     |      |  — |     |    $ |  0 |     |    $ |  1 |     |    $ |  2 |     |    $ |  3 |     |    $ |  3 |
| Total Revenue                |     |      |    |     |    $ | 28 |   |     |    $ | 31 |     |    $ | 32 |     |    $ | 34 |     |    $ | 36 |     |    $ | 37 |     |    $ | 38 |
| EBIT (1)